Literature DB >> 10065154

Regulation of p53 protein function through alterations in protein-folding pathways.

T R Hupp1.   

Abstract

The tumour suppressor protein p53 is a stress-activated transcription factor whose activity is required for regulating the cellular response to stress and damage. The biochemical activity of p53 as a transcription factor can be regulated by partner proteins affecting stability, nuclear transport, signalling pathways modulating phosphorylation and interactions with components of the transcriptional machinery. The key structural determinants of p53 protein that drive sequence-specific DNA binding include the core specific DNA-binding domain and the tetramerization domain. Flanking these domains are more evolutionarily divergent carboxy- and amino-terminal regulatory motifs that further modulate tetramerization and sequence-specific transactivation. This review will mainly focus on the mechanisms whereby the tetramerization domain modulates sequence-specific DNA binding and how missense point mutations in p53 protein and the activity of molecular chaperones may lead to unfolding of mutant p53 tetramers in human tumours.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065154     DOI: 10.1007/s000180050272

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  11 in total

Review 1.  Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.

Authors:  M Ljungman
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  Activation of p53 protein by telomeric (TTAGGG)n repeats.

Authors:  M Milyavsky; A Mimran; S Senderovich; I Zurer; N Erez; I Shats; N Goldfinger; I Cohen; V Rotter
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

3.  Role of tumor suppressor p53 domains in selective binding to supercoiled DNA.

Authors:  Marie Brázdová; Jan Palecek; Dmitry I Cherny; Sabina Billová; Miroslav Fojta; Petr Pecinka; Borivoj Vojtesek; Thomas M Jovin; Emil Palecek
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

4.  Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.

Authors:  Richard J Jones; Chad C Bjorklund; Veerabhadran Baladandayuthapani; Deborah J Kuhn; Robert Z Orlowski
Journal:  Mol Cancer Ther       Date:  2012-08-28       Impact factor: 6.261

5.  Evidence for allosteric effects on p53 oligomerization induced by phosphorylation.

Authors:  Petr Muller; Juliana M Chan; Oliver Simoncik; Miroslav Fojta; David P Lane; Ted Hupp; Borivoj Vojtesek
Journal:  Protein Sci       Date:  2017-12-08       Impact factor: 6.725

6.  Full-length p53 tetramer bound to DNA and its quaternary dynamics.

Authors:  Ö Demir; P U Ieong; R E Amaro
Journal:  Oncogene       Date:  2016-09-19       Impact factor: 9.867

7.  Defect in the p53-Mdm2 autoregulatory loop resulting from inactivation of TAF(II)250 in cell cycle mutant tsBN462 cells.

Authors:  C Wasylyk; B Wasylyk
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

8.  Sequence-dependent cooperative binding of p53 to DNA targets and its relationship to the structural properties of the DNA targets.

Authors:  Itai Beno; Karin Rosenthal; Michael Levitine; Lihi Shaulov; Tali E Haran
Journal:  Nucleic Acids Res       Date:  2010-11-10       Impact factor: 16.971

9.  Multimerization of the GATA4 transcription factor regulates transcriptional activity and cardiomyocyte hypertrophic response.

Authors:  Satoshi Shimizu; Yoichi Sunagawa; Naruto Hajika; Natsumi Yorimitsu; Yasufumi Katanasaka; Masafumi Funamoto; Yusuke Miyazaki; Nurmila Sari; Kana Shimizu; Koji Hasegawa; Tatsuya Morimoto
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

10.  P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer's disease.

Authors:  Kathleen M Farmer; Gaurav Ghag; Nicha Puangmalai; Mauro Montalbano; Nemil Bhatt; Rakez Kayed
Journal:  Acta Neuropathol Commun       Date:  2020-08-10       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.